Bailey Tianheng (688506) announced on the evening of May 29 that a phase III clinical trial of the innovative biopharmaceutical BL-B01D1 (EGFR×HER3-ADC) monotherapy developed independently by the company for locally advanced or metastatic non-small cell lung cancer with EGFR-sensitive mutations that failed EGFR-TKI treatment has recently completed the enrollment of the first test subjects.
百利天恒：某创新生物药III期临床试验完成首例受试者入组
Baili Tianheng: Phase III clinical trial of an innovative biopharmaceutical completed its first patient enrollment
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.